Creo Medical Group PLC
LSE:CREO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Creo Medical Group PLC
Cash from Operating Activities
Creo Medical Group PLC
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Creo Medical Group PLC
LSE:CREO
|
Cash from Operating Activities
-£22.2m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Smith & Nephew PLC
LSE:SN
|
Cash from Operating Activities
$1.3B
|
CAGR 3-Years
40%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Cash from Operating Activities
$254.3m
|
CAGR 3-Years
54%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
12%
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Cash from Operating Activities
£9.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Inspiration Healthcare Group PLC
LSE:IHC
|
Cash from Operating Activities
£4.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
|
EMV Capital PLC
LSE:EMVC
|
Cash from Operating Activities
-£1.4m
|
CAGR 3-Years
25%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
Creo Medical Group PLC
Glance View
Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.
See Also
What is Creo Medical Group PLC's Cash from Operating Activities?
Cash from Operating Activities
-22.2m
GBP
Based on the financial report for Dec 31, 2024, Creo Medical Group PLC's Cash from Operating Activities amounts to -22.2m GBP.
What is Creo Medical Group PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-13%
Over the last year, the Cash from Operating Activities growth was -3%. The average annual Cash from Operating Activities growth rates for Creo Medical Group PLC have been 5% over the past three years , -13% over the past five years .
